STAT News
STAT+: Key study of Grail’s cancer detection test fails in setback for company
STAT News · Feb 19, 2026 · Collected from RSS
Summary
Grail's blood test for detecting cancer early failed to meet its main goal in a giant study being conducted with England’s NHS, the company said.
Full Article
By Matthew HerperFeb. 19, 2026 Senior Writer, Medicine, Editorial Director of Events A blood test for detecting cancer early being developed by the diagnostics firm Grail failed to meet its main goal in a giant study being conducted with England’s National Health Service, the company said Thursday. Grail’s test has been the standard bearer for new technologies that promise a blood test can be used to detect many different types of cancer early and eventually even to indicate to scientists where in the body to look for tumors. The company already sells its test, called Galleri, for a list price of $1,000, although it is not yet approved by the Food and Drug Administration. Grail said Thursday it sold 185,000 tests in 2025, generating $136.8 million. The company’s shares were down 47% in after-hours trading. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe
Share this story